Gilead Sciences, Inc. (Nasdaq: GILD) announced it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology...
New “Danaher Beacon,” first in the European Union, aims to accelerate translation, scalability, and reliability across cell and gene therap...
Imaginostics, Inc. announced that it has received a Letter of Support from Siemens Healthineers in connection with ongoing exploratory discussions ...
In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination ...
Curi Bio, a world leader in human-relevant 3D tissue technology, and Battelle, the world’s largest independent nonprofit research and development o...
Study conducted in collaboration with the Neuroregeneration Institute at McLean Hospital Autologous neuronal cell therapy for Parkinson’s diseas...
For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1 Participants taking retatrut...
Congruence Therapeutics announced that the first participant has been dosed in its Phase 1/1b clinical trial evaluating CGX-926, an oral small-mole...
Curia, a leading contract research, development and manufacturing organization (CDMO), announced progress on the expansion at its Glasgow, UK sterile dru...
Primary endpoint met in Phase 3 TALAPRO-3 study demonstrating a statistically significant and clinically meaningful reduction in risk of disease prog...
— $9M Second Phase of CDMO Investment Builds on 2025 $6M Expansion, Funding Facility Upgrades and Increased Capacity for Suppository, Semi-Solid,...
TRI-611 is an oral investigational small molecule therapy designed as a potent, brain-penetrant molecular glue degrader, engaging the body’s in...
Reimagining early-stage drug discovery leveraging NVIDIA BioNeMo Framework -- Persistent Systems (BSE: 533179) (NSE: PERS...
The Atlas will expand known evolutionary genetic diversity by 100x, collecting novel genomic data from over 100 million new species...
© 2026 Biopharma Boardroom. All Rights Reserved.
